Ken KY Ho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3596986/publications.pdf

Version: 2024-02-01

all docs

191 14,134 57 114 papers citations h-index g-index

202 202 202 8313

times ranked

citing authors

docs citations

#	Article	IF	CITATIONS
1	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
2	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
3	The NETting of pituitary adenoma: a gland illusion. Pituitary, 2022, 25, 349-351.	1.6	12
4	Growth Hormone Stops Excessive Inflammation After Partial Hepatectomy, Allowing Liver Regeneration and Survival Through Induction of H2â€Bl/HLAâ€G. Hepatology, 2021, 73, 759-775.	3.6	24
5	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
6	A Novel Liver-Targeted Testosterone-Therapy for Sarcopenia in Androgen Deprived Men with Prostate Cancer. Journal of the Endocrine Society, 2021, 5, bvab116.	0.1	5
7	MECHANISMS IN ENDOCRINOLOGY: Paracrine and endocrine control of the growth hormone axis by estrogen. European Journal of Endocrinology, 2021, 184, R269-R278.	1.9	13
8	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
9	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
10	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. Pituitary, 2020, 23, 476-477.	1.6	18
11	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	2.6	183
12	Letter to the Editor: "Twice as High Diet-Induced Thermogenesis After Breakfast vs Dinner on High-Calorie as Well as Low-Calorie Meals― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2671-e2672.	1.8	0
13	MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly?. European Journal of Endocrinology, 2020, 182, R67-R82.	1.9	37
14	The promise of growth hormone in sport: doped or duped. Archives of Endocrinology and Metabolism, 2020, 63, 576-581.	0.3	5
15	The Use and Abuse of Growth Hormone in Sports. Endocrine Reviews, 2019, 40, 1163-1185.	8.9	34
16	A tale of pituitary adenomas: to NET or not to NET. Pituitary, 2019, 22, 569-573.	1.6	60
17	Disparate Effect of Aromatization on the Central Regulation of GH Secretion by Estrogens in Men and Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2978-2984.	1.8	8
18	Prevalence and Correlates of PrEP Awareness and Use Among Black Men Who Have Sex with Men and Women (MSMW) in the United States. AIDS and Behavior, 2019, 23, 2694-2705.	1.4	22

#	Article	IF	CITATIONS
19	Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placeboâ€controlled crossâ€over study. Diabetes, Obesity and Metabolism, 2019, 21, 509-516.	2.2	40
20	A 5αâ€reductase (SRD5A2) polymorphism is associated with serum testosterone and sex hormone–binding globulin in men, while aromatase (CYP19A1) polymorphisms are associated with oestradiol and luteinizing hormone reciprocally. Clinical Endocrinology, 2019, 90, 301-311.	1.2	3
21	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 2018, 7, R126-R134.	0.8	39
22	Paul Lee, 1977-2017. Internal Medicine Journal, 2018, 48, 381-382.	0.5	0
23	Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of <scp>IGF</scp> 1. Clinical Endocrinology, 2018, 88, 333-340.	1.2	20
24	Decorin, a growth hormone-regulated protein in humans. European Journal of Endocrinology, 2018, 178, 145-152.	1.9	16
25	Glucocorticoids suppress brown adipose tissue function in humans: A doubleâ€blind placeboâ€controlled study. Diabetes, Obesity and Metabolism, 2018, 20, 840-848.	2.2	43
26	A will and a way to fund medicines for rare diseases: the story of human growth hormone replacement for adults with growth hormone deficiency. Internal Medicine Journal, 2018, 48, 999-1002.	0.5	2
27	Diet-induced thermogenesis: fake friend or foe?. Journal of Endocrinology, 2018, 238, R185-R191.	1.2	27
28	Testosterone prevents protein loss via the hepatic urea cycle in human. European Journal of Endocrinology, 2017, 176, 489-496.	1.9	18
29	Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development. European Journal of Endocrinology, 2017, 177, 137-143.	1.9	25
30	Predictors for secondary therapy after surgical resection of nonfunctioning pituitary adenomas. Clinical Endocrinology, 2017, 87, 717-724.	1.2	13
31	Sex steroids and the GH axis: Implications for the management of hypopituitarism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 59-69.	2.2	42
32	Plasma biomarker proteins for detection of human growth hormone administration in athletes. Scientific Reports, 2017, 7, 10039.	1.6	34
33	Longitudinal evaluation of the natural history of conservatively managed nonfunctioning pituitary adenomas. Clinical Endocrinology, 2016, 84, 222-228.	1.2	25
34	Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 2016, 174, C1-C8.	1.9	99
35	MECHANISMS IN ENDOCRINOLOGY: Brown adipose tissue in humans: regulation and metabolic significance. European Journal of Endocrinology, 2016, 175, R11-R25.	1.9	19
36	Growth hormone (<scp>GH</scp>) enhances anaerobic capacity: impact on physical function and quality of life in adults with <scp>GH</scp> deficiency. Clinical Endocrinology, 2016, 85, 660-668.	1.2	23

3

#	Article	IF	Citations
37	Hypopituitarism and Growth Hormone Deficiency. , 2016, , 188-208.e5.		4
38	Pituitary Physiology and Diagnostic Evaluation. , 2016, , 176-231.		17
39	Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. European Journal of Endocrinology, 2015, 173, 479-487.	1.9	7
40	Formoterol, a Highly \hat{I}^2 2-Selective Agonist, Induces Gender-Dimorphic Whole Body Leucine Metabolism in Humans. Metabolism: Clinical and Experimental, 2015, 64, 506-512.	1.5	19
41	A critical evaluation of bioimpedance spectroscopy analysis in estimating body composition during GH treatment: comparison with bromide dilution and dual X-ray absorptiometry. European Journal of Endocrinology, 2015, 172, 21-28.	1.9	20
42	Impairment of Anaerobic Capacity in Adults With Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1811-1818.	1.8	13
43	Effects of glucocorticoids on human brown adipocytes. Journal of Endocrinology, 2015, 224, 139-147.	1.2	47
44	Adverse effects of androgenâ€deprivation therapy in prostate cancer and their management. BJU International, 2015, 115, 3-13.	1.3	109
45	The Year in Pituitary 2014. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4449-4454.	1.8	3
46	Infrared thermography in the detection of brown adipose tissue in humans. Physiological Reports, 2014, 2, e12167.	0.7	69
47	Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women. European Journal of Endocrinology, 2014, 170, 375-383.	1.9	13
48	Action of GH on skeletal muscle function: molecular and metabolic mechanisms. Journal of Molecular Endocrinology, 2014, 52, R107-R123.	1.1	81
49	Growth Hormone Should Be Used Only for Approved Indications. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 409-411.	1.8	22
50	Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology, 2014, 10, 243-248.	4.3	306
51	Brown Adipose Tissue in Adult Humans: A Metabolic Renaissance. Endocrine Reviews, 2013, 34, 413-438.	8.9	164
52	Effect of short-term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy. European Journal of Endocrinology, 2013, 168, 243-251.	1.9	11
53	Oral low-dose testosterone administration induces whole-body protein anabolism in postmenopausal women: a novel liver-targeted therapy. European Journal of Endocrinology, 2013, 169, 321-327.	1.9	14
54	Associations of IGF1 and its binding proteins with abdominal aortic aneurysm and aortic diameter in older men. European Journal of Endocrinology, 2012, 166, 191-197.	1.9	18

#	Article	IF	CITATIONS
55	Differential Effects of Raloxifene and Estrogen on Body Composition in Growth Hormone-Replaced Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1005-1012.	1.8	12
56	Gender Difference in the Neuroendocrine Regulation of Growth Hormone Axis by Selective Estrogen Receptor Modulators. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E521-E527.	1.8	27
57	Patching up a better pill for GH-deficient women. Nature Reviews Endocrinology, 2012, 8, 197-198.	4.3	8
58	Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency. Medical Journal of Australia, 2012, 197, 204-205.	0.8	6
59	Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care. Medical Journal of Australia, 2012, 196, 237-239.	0.8	3
60	Growth Hormone in Sports: Detecting the Doped or Duped. Hormone Research in Paediatrics, 2011, 76, 84-90.	0.8	10
61	Hypothalamic/Pituitary Morbidity in Skull Base Pathology. Otolaryngologic Clinics of North America, 2011, 44, 1005-1021.	0.5	0
62	Growth hormone and physical performance. Trends in Endocrinology and Metabolism, 2011, 22, 171-178.	3.1	60
63	High Prevalence of Brown Adipose Tissue in Adult Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2450-2455.	1.8	107
64	Identification of Novel GH-Regulated Pathway of Lipid Metabolism in Adipose Tissue: A Gene Expression Study in Hypopituitary Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1188-E1196.	1.8	31
65	Interaction between Testosterone and Growth Hormone on Whole-Body Protein Anabolism Occurs in the Liver. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1060-1067.	1.8	31
66	Inducible Brown Adipogenesis of Supraclavicular Fat in Adult Humans. Endocrinology, 2011, 152, 3597-3602.	1.4	79
67	Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: the Health In Men Study. European Journal of Endocrinology, 2011, 164, 715-723.	1.9	34
68	Prevalence and Incidence of Diabetes Mellitus in Adult Patients on Growth Hormone Replacement for Growth Hormone Deficiency: A Surveillance Database Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2255-2261.	1.8	60
69	Detection of Growth Hormone Doping in Sport Using Growth Hormone-Responsive Markers. Growth Hormone, 2011, , 139-150.	0.2	1
70	Pituitary Physiology and Diagnostic Evaluation. , 2011, , 175-228.		27
71	Growth Hormone in Sports: Is There Evidence of Benefit?. , 2011, , 389-404.		0
72	The Effects of Growth Hormone on Body Composition and Physical Performance in Recreational Athletes. Annals of Internal Medicine, 2010, 152, 568.	2.0	116

#	Article	IF	Citations
73	Misleading Interpretations and Public Misinformation on Human Growth Hormone in Athletes. Annals of Internal Medicine, 2010, 153, 346.	2.0	0
74	A Consensus on Criteria for Cure of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3141-3148.	1.8	697
75	IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men. European Journal of Endocrinology, 2010, 162, 249-257.	1.9	38
76	A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E601-E606.	1.8	269
77	Hyponatremia in Pulmonary TB. Chest, 2010, 137, 207-208.	0.4	44
78	Paracrine Regulation of Growth Hormone Secretion by Estrogen in Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3771-3776.	1.8	20
79	Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2099-2106.	1.8	18
80	Neuroendocrine Regulation of Growth Hormone and Androgen Axes by Selective Estrogen Receptor Modulators in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5443-5448.	1.8	17
81	Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 74-81.	1.8	113
82	Growth Hormone Administration: Is It Safe and Effective for Athletic Performance. Endocrinology and Metabolism Clinics of North America, 2010, 39, 11-23.	1.2	16
83	Hypopituitarism and Growth Hormone Deficiency. , 2010, , 243-261.		O
84	Guidelines for Acromegaly Management: An Update. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1509-1517.	1.8	701
85	Growth hormone supplementation: a silver lining for the aged?. Nature Reviews Endocrinology, 2009, 5, 424-425.	4.3	1
86	Proteomic Profiling of Growth Hormone-Responsive Proteins in Human Peripheral Blood Leukocytes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3038-3043.	1.8	17
87	Detection of Growth Hormone Doping by Gene Expression Profiling of Peripheral Blood. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4703-4709.	1.8	29
88	Growth hormone receptor modulators. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 145-156.	2.6	58
89	Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. Clinical Endocrinology, 2009, 71, 82-85.	1.2	24
90	Testosterone stimulates extraâ€hepatic but not hepatic fat oxidation (Fox): comparison of oral and transdermal testosterone administration in hypopituitary men. Clinical Endocrinology, 2009, 71, 715-721.	1.2	26

#	Article	IF	CITATIONS
91	WEIGHT MAINTENANCE IN HOSPITALIZED GERIATRIC PATIENTS TREATED WITH BETAâ€BLOCKERS. Journal of the American Geriatrics Society, 2009, 57, 1125-1126.	1.3	0
92	Demographic factors influencing the GH system: Implications for the detection of GH doping in sport. Growth Hormone and IGF Research, 2009, 19, 327-332.	0.5	8
93	A robust test for growth hormone doping $\hat{a} \in \hat{a}$ present status and future prospects. Asian Journal of Andrology, 2008, 10, 416-425.	0.8	28
94	Relationship between GH-induced metabolic changes and changes in body composition: A dose and time course study in GH-deficient adults. Growth Hormone and IGF Research, 2008, 18, 55-64.	0.5	24
95	Within-Subject Variability and Analytic Imprecision of Insulinlike Growth Factor Axis and Collagen Markers: Implications for Clinical Diagnosis and Doping Tests. Clinical Chemistry, 2008, 54, 1268-1276.	1.5	60
96	Pharmacodynamics of Growth Hormone Abuse Biomarkers and the Influence of Gender and Testosterone: A Randomized Double-Blind Placebo-Controlled Study in Young Recreational Athletes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2213-2222.	1.8	52
97	Can a single growth hormone level be used to assess disease activity after treatment of acromegaly?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 74-75.	2.9	1
98	Impact of Growth Hormone and Dehydroepiandrosterone on Protein Metabolism in Glucocorticoid-Treated Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 688-695.	1.8	10
99	Acute Adrenal Crisis. , 2008, , 45-62.		0
100	Growth hormone regulation of metabolic gene expression in muscle: a microarray study in hypopituitary men. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E364-E371.	1.8	47
101	Abuse of growth hormone by athletes. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 198-199.	2.9	16
102	Protein Metabolism in Acromegaly: Differential Effects of Short- and Long-Term Treatment. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1479-1484.	1.8	28
103	Impact of Acute and Chronic Low-Dose Glucocorticoids on Protein Metabolism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3923-3929.	1.8	20
104	Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases. Endocrinology, 2007, 148, 2417-2423.	1.4	9
105	Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology, 2007, 157, 695-700.	1.9	550
106	Regulation of Growth Hormone Action by Gonadal Steroids. Endocrinology and Metabolism Clinics of North America, 2007, 36, 57-73.	1.2	38
107	Protein metabolism in glucocorticoid excess: study in Cushing's syndrome and the effect of treatment. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1426-E1432.	1.8	31
108	Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary, 2007, 10, 165-172.	1.6	14

#	Article	IF	CITATIONS
109	Newer options in the management of acromegaly. Internal Medicine Journal, 2006, 36, 437-444.	0.5	16
110	Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clinical Endocrinology, 2006, 64, 436-443.	1.2	51
111	Modulation of growth hormone action by sex steroids. Clinical Endocrinology, 2006, 65, 413-422.	1.2	182
112	Regulating of Growth Hormone Sensitivity by Sex Steroids: Implications for Therapy. , 2006, 35, 115-128.		31
113	Endocrinology: the next 60 years. Journal of Endocrinology, 2006, 190, 3-6.	1.2	9
114	Influence of Demographic Factors and Sport Type on Growth Hormone-Responsive Markers in Elite Athletes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4424-4432.	1.8	49
115	Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E266-E271.	1.8	113
116	Consensus statement: medical management of acromegaly. European Journal of Endocrinology, 2005, 153, 737-740.	1.9	212
117	Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3897-3903.	1.8	46
118	Independent and Combined Effects of Testosterone and Growth Hormone on Extracellular Water in Hypopituitary Men. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3989-3994.	1.8	88
119	Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes. Clinical Endocrinology, 2005, 63, 305-309.	1.2	11
120	9: Pituitary disease in adults. Medical Journal of Australia, 2004, 180, 419-425.	0.8	15
121	Estrogen Up-Regulates Hepatic Expression of Suppressors of Cytokine Signaling-2 and -3 in Vivo and in Vitro. Endocrinology, 2004, 145, 5525-5531.	1.4	69
122	Estrogen Regulation of Growth Hormone Action. Endocrine Reviews, 2004, 25, 693-721.	8.9	430
123	Comparison of Efficacy and Tolerability of Somatostatin Analogs and Other Therapies for Acromegaly. Endocrine, 2003, 20, 299-306.	2.2	16
124	Xanthomatous Pituitary Lesions: A Report of Two Cases and Review of the Literature. Pituitary, 2003, 6, 161-168.	1.6	84
125	Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clinical Endocrinology, 2003, 59, 690-698.	1.2	30
126	Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4759-4767.	1.8	85

#	Article	IF	CITATIONS
127	Physiological and pharmacological regulation of 20-kDa growth hormone. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E836-E843.	1.8	62
128	Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency?. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 477-485.	1.8	277
129	Human Growth Hormone Replacement in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and Lipid Status—3-Year Results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1600-1606.	1.8	109
130	Short-Term Safety and Efficacy of Human GH Replacement Therapy in 595 Adults with GH Deficiency: A Comparison of Two Dosage Algorithms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1974-1979.	1.8	46
131	Guidelines for Acromegaly Management. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4054-4058.	1.8	334
132	Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. Journal of Hepatology, 2002, 36, 751-758.	1.8	53
133	Growth hormone replacement therapy for adults: Into the new millennium. Growth Hormone and IGF Research, 2002, 12, 1-33.	0.5	90
134	Galanin in human pituitary adenomas: frequency and clinical significance. Clinical Endocrinology, 2002, 56, 397-403.	1.2	23
135	A novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays. Clinical Endocrinology, 2002, 56, 475-485.	1.2	17
136	Human Growth Hormone Replacement in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and Lipid Status–3-Year Results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1600-1606.	1.8	88
137	Measurement of growth hormone, insulin-like growth factor I and their binding proteins: the clinical aspects. Clinica Chimica Acta, 2001, 313, 119-123.	0.5	24
138	Place of pegvisomant in acromegaly. Lancet, The, 2001, 358, 1743-1744.	6.3	16
139	Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E1191-E1196.	1.8	98
140	State-of-the-Art Strategies for the Diagnosis and Management of Acromegaly. , 2001, 11, 223-232.		5
141	Growth hormone replacement therapy in adults. Current Opinion in Endocrinology, Diabetes and Obesity, 2000, 7, 89-95.	0.6	2
142	Diagnosis and Management of Adult Growth Hormone Deficiency. Endocrine, 2000, 12, 189-196.	2.2	4
143	Route-Dependent Endocrine and Metabolic Effects of Estrogen Replacement Therapy. Journal of Pediatric Endocrinology and Metabolism, 2000, 13, 1457-1466.	0.4	11
144	Estrogens Exert Route- and Dose-Dependent Effects on Insulin-Like Growth Factor (IGF)-Binding Protein-3 and the Acid-Labile Subunit of the IGF Ternary Complex*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1918-1922.	1.8	83

#	Article	IF	Citations
145	Distribution and Abundance of Messenger Ribonucleic Acid for Growth Hormone Receptor Isoforms in Human Tissues1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2865-2871.	1.8	68
146	Insulin Regulation of Human Hepatic Growth Hormone Receptors: Divergent Effects on Biosynthesis and Surface Translocation 1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4712-4720.	1.8	196
147	Criteria for Cure of Acromegaly: A Consensus Statement ¹ â€. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 526-529.	1.8	779
148	Diagnosis of adult GH deficiency. Lancet, The, 2000, 356, 1125-1126.	6.3	28
149	Criteria for Cure of Acromegaly: A Consensus StatementÂ. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 526-529.	1.8	839
150	Insulin Regulation of Human Hepatic Growth Hormone Receptors: Divergent Effects on Biosynthesis and Surface Translocation. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4712-4720.	1.8	164
151	Placental Growth Hormone (GH), GH-Binding Protein, and Insulin-Like Growth Factor Axis in Normal, Growth-Retarded, and Diabetic Pregnancies: Correlations with Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1143-1150.	1.8	118
152	Estrogens Exert Route- and Dose-Dependent Effects on Insulin-Like Growth Factor (IGF)-Binding Protein-3 and the Acid-Labile Subunit of the IGF Ternary Complex. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1918-1922.	1.8	57
153	Distribution and Abundance of Messenger Ribonucleic Acid for Growth Hormone Receptor Isoforms in Human Tissues. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2865-2871.	1.8	54
154	Initial characterization of the GH-IGF axis and nutritional status of the Ati Negritos of the Philippines. Clinical Endocrinology, 1999, 51, 741-747.	1.2	16
155	Effect of Estrogen on GH Secretion and Action in Postmenopausal Women. , 1999, , 54-66.		1
156	The Diagnosis of Adult Growth Hormone Deficiency. Growth Hormone, 1999, , 109-126.	0.2	1
157	How Is Whole Body Protein Turnover Perturbed in Growth Hormone-Deficient Adults?1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4344-4349.	1.8	35
158	The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women Journal of Clinical Investigation, 1998, 102, 1035-1040.	3.9	187
159	How Is Whole Body Protein Turnover Perturbed in Growth Hormone-Deficient Adults?. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4344-4349.	1.8	36
160	Stimulation of Mitochondrial Fatty Acid Oxidation by Growth Hormone in Human Fibroblasts1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4208-4213.	1.8	27
161	Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: A novel mechanism of growth hormone receptor regulation. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11381-11386.	3.3	36
162	The Diagnosis of Growth Hormone Deficiency in Adults. Clinical Pediatric Endocrinology, 1997, 6, 35-37.	0.4	0

#	Article	IF	CITATIONS
163	Human growth hormone fragment (hGH44–191) produces insulin resistance and hyperinsulinemia but is less potent than the 22 kDa hGH in the rat. Endocrine, 1997, 6, 47-52.	2.2	11
164	Stimulation of Mitochondrial Fatty Acid Oxidation by Growth Hormone in Human Fibroblasts. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4208-4213.	1.8	30
165	Growth hormone treatment of subfertile males. Fertility and Sterility, 1996, 66, 292-298.	0.5	44
166	Impaired growth hormone secretion and increased growth hormone-binding protein levels in subfertile males. Fertility and Sterility, 1996, 65, 165-169.	0.5	22
167	Sex Steroid Regulation of Growth Hormone Secretion and Action. Hormone Research, 1996, 45, 67-73.	1.8	66
168	Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1123-1128.	1.8	58
169	A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1591-1597.	1.8	27
170	Growth hormone-induced insulin resistance and its relationship to lipid availability in the rat. Diabetes, 1996, 45, 415-421.	0.3	9
171	Oestrogen effects on calcitriol levels in postâ€menopausal women: a comparison of oral versus transdermal administration. Clinical Endocrinology, 1995, 43, 219-224.	1.2	37
172	Estrogen, Lipid Oxidation, and Body Fat. New England Journal of Medicine, 1995, 333, 669-670.	13.9	39
173	Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study. European Journal of Endocrinology, 1995, 133, 65-70.	1.9	29
174	Defining growth hormone deficiency in adults. Metabolism: Clinical and Experimental, 1995, 44, 91-96.	1.5	24
175	Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 72-77.	1.8	85
176	Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3395-3402.	1.8	131
177	Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 480-485.	1.8	57
178	Energy metabolism and substrate oxidation in acromegaly. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 486-491.	1.8	14
179	A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 1783-1788.	1.8	73
180	Growth Hormone Economy in Hypogonadism: Effects of Sex Steroids. , 1995, , 160-171.		0

#	Article	IF	Citations
181	Characterization of 24â€hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical Endocrinology, 1994, 41, 75-83.	1.2	110
182	Effect of Octreotide, a Somatostatin Analog, on Sleep Apnea in Patients with Acromegaly. Annals of Internal Medicine, 1994, 121, 478.	2.0	116
183	Body composition and energy expenditure in acromegaly. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 381-386.	1.8	69
184	Different modes of growth hormone (GH) administration do not change GH binding protein activity in man. Clinical Endocrinology, 1993, 38, 143-148.	1.2	36
185	Effects of different oral oestrogen formulations on insulinâ€like growth factorâ€l, growth hormone and growth hormone binding protein in postâ€menopausal women. Clinical Endocrinology, 1993, 39, 561-567.	1.2	151
186	Aging and Growth Hormone. Hormone Research, 1993, 40, 80-86.	1.8	65
187	Angiotensinogen Secretion by Single Rat Pituitary Cells: Detection by a Reverse Haemolytic Plaque Assay and Cell Identification by Immunocytochemistry. Neuroendocrinology, 1992, 55, 308-316.	1.2	24
188	Impact of octreotide, a longâ€acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clinical Endocrinology, 1992, 36, 271-279.	1.2	72
189	Impact of short-term estrogen administration on growth hormone secretion and action: Distinct route-dependent effects on connective and bone tissue metabolism. Journal of Bone and Mineral Research, 1992, 7, 821-827.	3.1	85
190	Dual Defects in Pulsatile Growth Hormone Secretion and Clearance Subserve the Hyposomatotropism of Obesity in Man*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 51-59.	1.8	472
191	Contrasting Effects of Oral and Transdermal Routes of Estrogen Replacement Therapy on 24-Hour Growth Hormone (GH) Secretion, Insulin-Like Growth Factor I, and GH-Binding Protein in Postmenopausal Women*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 374-381.	1.8	499